AUTHOR=Zhang Mengdi , Zhang Yingna , Liu Peipei , Gao Qingye , Liu Qian , Zhou Xinyue , Liu Ruichen , Zhao Xue , Zhang Jing , Hu Jia , Dong Haiyan , Liu Jing , Yang Junhong , Ruan Zhe , Chang Ting , Lv Jie , Gao Feng 

TITLE=Anti-ALDOA antibody: a novel diagnostic-associated autoantibody in myasthenia gravis

JOURNAL=Frontiers in Neurology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1696583

DOI=10.3389/fneur.2025.1696583

ISSN=1664-2295

ABSTRACT=This study identified novel autoantibodies in patients with seronegative myasthenia gravis (SNMG).Autoantibodies in SNMG sera were screened using a targeted binding assay (TBA). The target antigen was identified via immunoprecipitation and mass spectrometry, and validated by western blotting using a commercial antigen. A cell-based assay (CBA) employing HEK293 cells expressing the identified antigen was established to detect specific antibodies in 676 MG patients and 20 controls.Aldolase A (ALDOA) was identified as a novel autoantigen. Anti-ALDOA antibodies (ALDOA-Ab) demonstrated high diagnostic specificity in SNMG and were also detected in seropositive MG patients, with positivity rates of 4.89% in AChR-Ab’ and 2.86% in MuSK-Ab’ subgroups. ALDOA-Ab was predominantly of the IgG1 subclass. ALDOA-Ab may serve as a potential diagnostic biomarker for MG. Further studies are needed to investigate its pathogenic role.